Nuveen Asset Management LLC Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)

Nuveen Asset Management LLC raised its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 452.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 837,082 shares of the biopharmaceutical company's stock after buying an additional 685,557 shares during the period. Nuveen Asset Management LLC owned about 1.20% of Xencor worth $19,236,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Barclays PLC boosted its holdings in Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after purchasing an additional 78,066 shares during the period. KBC Group NV raised its stake in Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 813 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Xencor by 24.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company's stock valued at $341,000 after buying an additional 2,946 shares in the last quarter. Yousif Capital Management LLC raised its stake in Xencor by 10.2% in the fourth quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company's stock valued at $482,000 after buying an additional 1,944 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its stake in Xencor by 12.7% in the fourth quarter. State of Alaska Department of Revenue now owns 39,773 shares of the biopharmaceutical company's stock valued at $913,000 after buying an additional 4,487 shares in the last quarter.

Insider Buying and Selling at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares of the company's stock, valued at approximately $542,334.07. The trade was a 8.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.76% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on XNCR. Barclays cut their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. Wedbush reiterated an "outperform" rating and set a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. Wells Fargo & Company cut their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. William Blair began coverage on Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. Finally, Wall Street Zen cut Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.50.

Xencor Stock Performance

Shares of NASDAQ XNCR traded up $0.12 during midday trading on Thursday, reaching $7.67. 98,636 shares of the company were exchanged, compared to its average volume of 655,393. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24. The stock has a fifty day simple moving average of $9.34 and a 200 day simple moving average of $16.42. The stock has a market cap of $545.88 million, a P/E ratio of -2.40 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. During the same period in the prior year, the firm posted ($1.11) EPS. Xencor's revenue for the quarter was up 104.6% compared to the same quarter last year. On average, research analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.